Pharmafile Logo
Pharmafocus logo
Advanced Search
amgen_flag

Court sides with Amgen in Sandoz’ challenge over patent on Enbrel

August 12, 2019
Sales and Marketing Enbrel, IP, Novartis Amgen, court, patent, pharma

A US court has sided with Amgen in a legal battle over the patent on blockbuster rheumatoid arthritis drug Enbrel. …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

August 9, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, CAR T, CAR-T, Eli Lilly, Lexicon, Medicare, Novartis, Pfizer, Sanofi, pharma

This week’s top story covered the scandal surrounding Novartis over its covering up of faulty data from the FDA. The …

News

MS drug boosts effectiveness of cancer therapy in treating glioblastoma, study shows

August 9, 2019
Medical Communications MS, brain cancer, glioblastoma, oncology, pharma

The multiple sclerosis (MS) drug teriflunomide boosts the effectiveness of cancer drugs in treating glioblastoma, according to researchers from UC, …

News
1920px-hiv-budding-color

Scientists use duoCAR-T therapy to fight HIV

August 9, 2019
Medical Communications AIDS, CAR-T therapy, HIV, health, immunotherapy, pharma

Researchers from the University of Pittsburgh, working with the biotech Lentigen, have found that an advanced form of CAR-T therapy …

News
astrazeneca_plaque

AstraZeneca’s Tagrisso improves overall survival in lung cancer in Phase 3 trial

August 9, 2019
Medical Communications AstraZeneca, Cancer, Tagrisso, lung cancer, oncology, pharma

AstraZeneca has said its cancer drug Tagrisso significantly improved overall survival in a Phase 3 study of patients with lung …

News
bayercross3

Bayer buys BlueRock Therapeutics for $600 million

August 9, 2019
Medical Communications Bayer, BlueRock, acquisitions, cell therapies, pharma

Bayer has entered into an agreement to fully acquire engineered cell therapy firm BlueRock Therapeutics in a deal worth $600 …

News
shutterstock_159488225

Transgene terminates oncolytic IO combo trial in advanced liver cancer

August 8, 2019
Research and Development Cancer, Transgene, clinical trials, liver cancer, pharma

Biotech firm Transgene has announced its decision to terminate a study investigating the efficacy of its oncolytic immunotherapy product Pexa-Vec …

News
101817_tumorsmyeloidsuppressorcells

Medicare will cover CAR-T therapies in United States

August 8, 2019
Sales and Marketing CAR-T therapies, Cancer, Gilead, Kymriah, Medicare, Novartis, keytruda, pharma

Medicare will cover the cost of Novartis’ and Gilead’s CAR-T therapies Kymriah and Yescarta, the US Centers for Medicare and …

News
merck-keytruda

Keytruda/chemo combo recommended for first-line lung cancer via Cancer Drugs Fund

August 8, 2019
Sales and Marketing CDF, Cancer, MSD, NHS, NICE, UK, keytruda, lung cancer, pharma

MSD’s Keytruda (pembrolizumab) has secured recommendation from NICE for inclusion on the Cancer Drugs Fund (CDF) in combination with chemotherapy …

News
gilead-sciences

Gilead’s PrEP drug Descovy should be approved for men and transgender women but not cis-gender women, FDA advisory panel says

August 8, 2019
Research and Development AIDS, Gilead, HIV, PrEP, descovy, pharma

Independent experts on a panel advising the FDA have voted in favour of Gilead’s new PrEP drug Descovy in men …

News

Rhythm Pharma’s obesity drug shows positive results in two Phase 3 trials

August 8, 2019
Research and Development Rhythm pharma, clinical trial, health, obesity, pharma

Rhythm Pharma’s obesity drug setmelanotide achieved positive results in two pivotal Phase 3 trials. In both studies, setmelanotide met its …

News
dupixentpackage

Sanofi’s Dupixent improves skin clearance in paediatric atopic dermatitis

August 7, 2019
Research and Development Dupixent, Sanofi, atopic dermatitis, pharma

As the therapy secured approval in Europe for treatment of adolescent patients with moderate-to-severe atopic dermatitis, Sanofi has revealed new …

News
astrazeneca_plaque

AstraZeneca’s Lynparza meets primary endpoint in Phase 3 prostate cancer trial

August 7, 2019
Research and Development Lynpraza, PARP inhibitor, lynparza, pharma, prostate cancer

AstraZeneca’s PARP inhibitor Lynparza was successful in improving progression free survival in a Phase 3 trial of patients with metastatic …

News

NICE recommends Pierre Fabre’s Nerlynx in adjuvant HER2+ breast cancer

August 7, 2019
Research and Development, Sales and Marketing Cancer, NCIE, NHS, Nerlynx, Pierre Fabre, UK, breast cancer

Pierre Fabre’s Nerlynx (neratinib) has been recommended by NICE as a new option for NHS patients with early hormone-receptor-positive, human …

News
medicinal_cannabis_uk_review

Medicinal cannabis company Spectrum makes first shipment into UK

August 7, 2019
Research and Development Spectrum, UK, cannabis, medicinalcannabis, pharma

Medicinal cannabis company Spectrum Europe has made its first shipment of cannabis into the UK, making it one of the …

News
novartis_window

Novartis hid faulty data from FDA over $2.1 million gene therapy Zolgensma

August 7, 2019
Research and Development AveXis, FDA, Novartis, Zolgensma, gene therapy, pharma

Novartis hid faulty data from the FDA until their drug was approved, according to a statement from Dr Peter Marks, …

News
troy_robinson

Troy Robinson promoted to managing director of Chugai Pharma Europe

August 6, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Troy Robinson has been taken on as the new managing director of Chugai Pharma Europe. Mike Crosher will succeed him …

Appointment
lilly_building_with_american_flag_web

Lilly’s Emgality smashes all Phase 3 endpoints in migraine sub-population

August 6, 2019
Manufacturing and Production, Research and Development Eli Lilly, Emgality, migraine, pharma

New Phase 3 data have been revealed on Eli Lilly’s Emgality (galcanezumab-gnlm), detailing its success in meeting all of its …

News
nice_new_london_office_internal_2_8

NICE reject Clovis Oncology’s ovarian cancer drug Rubraca

August 6, 2019
Manufacturing and Production NHS, NICE, Rubraca, UK, guidance, pharma

Britain’s cost-effectiveness body NICE has chosen not to recommend Clovis Oncology’s cancer drug Rubraca (rucaparib). On 6 August, NICE issued …

News

Takeda signs deal with Sosei Heptares worth $1.2 billion

August 6, 2019
Manufacturing and Production GPCR, Sosei Heptares, Takeda, pharma, sosei

Takeda has entered into a partnership with Sosei Heptares to develop drugs that modulate G protein-coupled receptor (GPCR) targets. The …

News
The Gateway to Local Adoption Series

Latest content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance

January 27, 2026

Crystalys Therapeutics appoints Justin Thacker as Chief Financial Officer

January 27, 2026

Rentschler Biopharma appoints Uwe Buecheler as interim CEO

January 26, 2026

Sandoz’ Ondibta receives European Commission approval for diabetes

January 26, 2026

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026